Orale Antidiabetika

Ashcroft FM (1996) Mechanism of the glycemic effects of sulfonylureas. Horm Metab Res 28:456PubMedCrossRefGoogle Scholar

Barman Balfour JA, Plosker GI (1999) Rosiglitazone. Drugs 57: 1–10Google Scholar

Chiasson JL, Gomis R, Hanefeld M et al (2002) Acarbose can prevent the progression of impaired glucose tolerance to type 2 diabetes mellitus. The STOP-NIDDM Trial. Lancet 359: 2072–2077PubMedCrossRefGoogle Scholar

Chilcott J, Tappendenden R Jones ML, Wright JP (2001) A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 23: 1792–1923PubMedCrossRefGoogle Scholar

Cusi K, DeFronzo RA (1998) Metformine review of its metabolic effects. Diabetes Reviews 6:89–131Google Scholar

Dunn CJ, Faulds D (2000) Nateglinide Drugs 60:607–615CrossRefGoogle Scholar

De Luis DA, Aller R, Terroba C, Ovalle H et al (2001) Effect on repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 24:1844–1845PubMedCrossRefGoogle Scholar

Feinglos M, Bethel M (1999) Therapy of type 2 diabetes, cardio-vascular death and the UGPD. Am Heart J 138:346–352CrossRefGoogle Scholar

Garber A, Duncan T, Goodman A et al (1997) Efficacy of metformin in type-II diabetes: results of a double-blind, placebo-controlled, dose-responsetrial. Am J Med 102:491–497CrossRefGoogle Scholar

Häring HU, Joost HC, Laube H et al (2001) Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Evidenzbasierte Diabetesleitlinien DDG. Hrg. Scherbaum WA., Landgraf R. Diabetes und Stoffwechsel 12(Suppl.2): 13–31Google Scholar

Klimt CR, Knatternd GL, Meinert CL et al (1970) The University Group Diabetes Program (UGDP I). A Study of the effects of hypoglycaemic effects on vascular complications in patients with adult onset diabetes. Diabetes 19(Suppl 2): 789–830.PubMedGoogle Scholar

Lebowitz HE (1998) Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diab Res 6:132–145Google Scholar

Malmberg K (1997) DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512–1515PubMedCentralPubMedCrossRefGoogle Scholar

Mather KM, Verma S, Anderson TJ (2001) Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coli Cardiol 37:1344–1350CrossRefGoogle Scholar

Martin S, Kolb H, Beuth J et al (2003) Change in body weight of patients after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes:a multicenter retrolective cohort study. Diabetologia 46:1611–1617PubMedCrossRefGoogle Scholar

Müller G, Satoh Y, Geisen K (1995) Extrapancreatic effects of sulfonylurea — a comparison between glimepiride and conventional sulfonylureas. Diabet Res Clin Pract 28:155CrossRefGoogle Scholar

Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents in Japanese patients with non-insulin-dependent diabetes mellitus: A randomised prospective 6-year study. Diabetes Res Clin Pract 28:103–117PubMedCrossRefGoogle Scholar

Olsson J, Lindberg G, Gottsäter M et al (2000) Increased mortality in Type II diabetec patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43:558–560PubMedCrossRefGoogle Scholar

Panthen U, Schwanstecher M, Schwanstecher C (1996) Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes 104:1–9CrossRefGoogle Scholar

Shichiri M, Kishikawa H, Ohkubo Y, Wake N (2000) Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23(Suppl 2): B21–B29PubMedGoogle Scholar

UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33) Lancet 352: 837–853CrossRefGoogle Scholar

UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRefGoogle Scholar

Wright A, Bürden ACF, Paisey RB et al (2002) Sulfonylurea inadequacy. Efficacy of addition of insulin over 6years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UPDS 57). Diabetes Care 25:330–336PubMedCrossRefGoogle Scholar

Yki-Järvinen H, Dressler A, Ziemen M (2000) HOE 901/3002 Study Group: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23:1130–1136PubMedCrossRefGoogle Scholar

Yki-Järvinen H (2001) Combination therapies with insulin in type 2 diabetes. Diabetes Care 24:758–767PubMedCrossRefGoogle Scholar